Guggenheim upgraded GSK to Buy from Neutral with a 2,031 GBp price target. The firm says its increased confidence in the company’s margin benefits points to attractive upside potential in the stock, particularly if the Zantac overhang resolves. The analyst is encouraged by GSK’s strong commercial execution around the launches of Arexvy and the long-acting HIV portfolio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- GSK confirms confidential settlement reached with Boyd/Steenvoord over Zantac
- GSK announces EAGLE-1 phase III trial met primary efficacy endpoint
- GSK announces LATITUDE phase III interim trial demonstrates ‘superior efficacy’
- GSK price target raised to 1,820 GBp from 1,650 GBp at Berenberg
- GSK completes acquisition of Aiolos Bio
